Domatinostat/Sirolimus

N/A

Report date: 2026/03/04 20:01:44

Base Information

Drug NameDomatinostat/Sirolimus
Drug Alias NameVUJ-100HLX-4310
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone deacetylase 2 inhibitorsHistone deacetylase 3 inhibitorsHistone deacetylase 1 inhibitors +[5] 
TargetsHistone deacetylase 2Histone deacetylase 1Histone deacetylase 3 +[5] 
Therapy Area/IndicationsOsteosarcoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsYes Domatinostat tosylateSirolimus
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesVuja De Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesHealx Ltd
Inactive CompaniesN/A
Active IndicationsOsteosarcoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A